Table 3. Relative survival rates (%) in patients with oesophageal squamous cell carcinoma, oesophageal adenocarcinoma, gastric cardia adenocarcinoma and gastric non-cardia adenocarcinoma in Sweden in 2000–2008, and follow-up until 2009.
| Relative survival rate (95% confidence interval) | |||||||
| Cancer | Sex and age groups | Number of patients (%) | 1 year | 3 years | 5 years | ||
| Esophageal squamous | Sex | Men | 1025 (61.9) | 35.6 (32.6–38.6) | 13.1 (10.9–15.4) | 9.6 (7.5–11.7) | |
| cell carcinoma | Women | 630 (38.1) | 38.6 (34.7–42.5) | 16.1 (12.9–19.2) | 11.4 (8.4–14.4) | ||
| Age (years) | <60 | 301 (18.2) | 50.4 (44.7–56.1) | 21.0 (16.2–25.8) | 16.0 (11.4–20.6) | ||
| 60–69 | 454 (27.4) | 40.8 (36.2–45.3) | 15.8 (12.2–19.4) | 13.0 (9.4–16.6) | |||
| 70–79 | 555 (33.5) | 34.1 (30.0––38.1) | 12.9 (9.8–16.0) | 8.9 (6.0–11.7) | |||
| ≥80 | 345 (20.8) | 22.1 (17.4––26.9) | 9.7 (5.7–13.8) | 3.7 (0.1–7.6) | |||
| Esophageal | Sex | Men | 1386 (81.2) | 42.6 (39.9–45.3) | 19.1 (16.9–21.4) | 15.3 (13.0–17.5) | |
| adenocarcinoma | Women | 321 (18.8) | 38.1 (32.6–43.6) | 15.4 (11.1–19.8) | 11.7 (7.5–15.9) | ||
| Age (years) | <60 | 344 (20.2) | 48.5 (43.2–53.8) | 21.7 (17.1–26.2) | 18.9 (14.4–23.5) | ||
| 60–69 | 485 (28.4) | 48.4 (43.9–52.9) | 24.5 (20.4–28.5) | 20.8 (16.8–24.9) | |||
| 70–79 | 494 (28.9) | 40.5 (36.0–44.9) | 18.4 (14.6–22.1) | 13.6 (9.8–17.3) | |||
| ≥80 | 384 (22.5) | 27.5 (22.7–32.4) | 7.8 (4.1–11.6) | 3.8 (0.3–7.2) | |||
| Gastric cardia | Sex | Men | 1331 (76.4) | 44.2 (41.4–47.0) | 19.5 (17.2–21.8) | 14.7 (12.4–17.0) | |
| adenocarcinoma | Women | 412 (23.6) | 37.9 (33.0–42.7) | 17.7 (13.6–21.7) | 13.1 (9.2–17.1) | ||
| Age (years) | <60 | 384 (22.0) | 51.5 (46.5–56.5) | 22.4 (18.0–26.7) | 17.1 (12.8–21.3) | ||
| 60–69 | 453 (26.0) | 48.3 (43.6–52.9) | 23.3 (19.2–27.5) | 17.4 (13.4–21.5) | |||
| 70–79 | 512 (29.4) | 40.4 (36.1–44.8) | 19.0 (15.3–22.8) | 14.2 (10.4–18.1) | |||
| ≥80 | 394 (22.6) | 29.1 (24.2–34.0) | 11.6 (7.5–15.7) | 10.8 (5.5–16.1) | |||
| Gastric non–cardia | Sex | Men | 3329 (56.7) | 44.6 (42.8–46.4) | 23.2 (21.6–24.9) | 19.1 (17.5–20.7) | |
| adenocarcinoma | Women | 2547 (43.3) | 42.7 (40.7–44.7) | 22.6 (20.8–24.4) | 18.8 (16.9–20.6) | ||
| Age (years) | <60 | 826 (14.1) | 52.1 (48.7–55.5) | 28.6 (25.5–31.8) | 23.8 (20.6–26.9) | ||
| 60–69 | 1137 (19.3) | 48.9 (45.9–51.8) | 25.6 (22.9–28.3) | 19.9 (17.2–22.6) | |||
| 70–79 | 1897 (32.3) | 44.0 (41.7–46.3) | 24.7 (22.6–26.9) | 21.5 (19.3–23.7) | |||
| ≥80 | 2016 (34.3) | 36.5 (34.2–38.8) | 18.1 (15.8–20.3) | 15.7 (13.2–18.2) | |||